Form 4: ResMed Director Sells Shares, Covers RSU Taxes

ResMed Director Jan De Witte reported the sale of 487 common shares and the disposition of 76.449 shares for tax withholding related to RSU vesting.

Summary

• Jan De Witte, a Director at ResMed Inc. (RMD), reported two transactions on November 11, 2025.
• De Witte sold 487 shares of ResMed Common Stock at a price of $250.25 per share, totaling approximately $121,871.75. This sale was executed under a Rule 10b5-1 plan adopted on February 3, 2025.
• Additionally, De Witte disposed of 76.449 shares of ResMed Common Stock at $250.1 per share, valued at approximately $19,120.19, to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) granted on November 20, 2024.
• Following these transactions, De Witte beneficially owns 5,242 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: The transactions are routine insider disclosures, involving a pre-planned sale and tax-related disposition of shares. They do not indicate a strong positive or negative sentiment towards the company's future prospects.

Positives

• The sale under a Rule 10b5-1 plan indicates pre-planned transactions, reducing concerns about opportunistic selling.
• The disposition for tax withholding is a standard practice for RSU vesting, not indicating a negative outlook.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a slight negative signal, though the amount is relatively small.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure for a director at ResMed, a leading company in medical devices for sleep apnea and respiratory care. Such transactions are common and typically do not reflect broader industry trends unless they are unusually large or widespread across multiple insiders.

Comparison to Industry Standards

• Insider transactions like these are standard disclosures across all publicly traded companies. The amounts involved for Jan De Witte are relatively small compared to the overall market capitalization of ResMed, which is a large-cap company.
• Similar routine sales or tax-related dispositions by directors are seen in companies like Philips (PHG) or Fisher & Paykel Healthcare (FPH) in the medical device sector, and these transactions are generally not considered significant indicators of company performance unless they represent a substantial portion of the insider's holdings or are part of a broader pattern of insider selling.

Related Party Transactions

• Disposition of 76.449 shares to the issuer for tax withholding on vesting of Restricted Stock Units is a common related party transaction for compensation purposes.

Stakeholder Impact

• Minimal direct impact on shareholders as the transaction volume is small relative to the company's total shares outstanding.
• No direct impact on employees, customers, suppliers, or creditors from these specific insider transactions.

Key Dates

Recommendation

The reported transactions are routine insider activities, specifically a pre-planned sale under a 10b5-1 plan and a disposition for tax withholding on RSU vesting. These are common and generally not indicative of a change in the company's fundamental outlook or a strong signal for future stock performance. The volume of shares is relatively small for a director of a company like ResMed. Therefore, based solely on this Form 4 filing, there is no new information to warrant a change from a 'hold' position, assuming an investor's existing thesis remains intact.

Keywords

ResMed, RMD, Jan De Witte, Insider Trading, Form 4, Stock Sale, RSU Vesting, 10b5-1 Plan, Director Transaction